دورية أكاديمية
Development of High-Level Echinocandin Resistance in a Patient With Recurrent Candida auris Candidemia Secondary to Chronic Candiduria.
| العنوان: | Development of High-Level Echinocandin Resistance in a Patient With Recurrent Candida auris Candidemia Secondary to Chronic Candiduria. |
|---|---|
| المؤلفون: | Biagi MJ; University of Illinois at Chicago College of Pharmacy, Department of Pharmacy Practice., Wiederhold NP; University of Texas Health Science Center at San Antonio, Department of Pathology and Laboratory Medicine, Fungus Testing Laboratory., Gibas C; University of Texas Health Science Center at San Antonio, Department of Pathology and Laboratory Medicine, Fungus Testing Laboratory., Wickes BL; University of Texas Health Science Center at San Antonio, Long School of Medicine, Department of Microbiology, Immunology, and Molecular Genetics., Lozano V; University of Texas Health Science Center at San Antonio, Long School of Medicine, Department of Microbiology, Immunology, and Molecular Genetics., Bleasdale SC; University of Illinois at Chicago College of Medicine, Department of Medicine., Danziger L; University of Illinois at Chicago College of Pharmacy, Department of Pharmacy Practice. |
| المصدر: | Open forum infectious diseases [Open Forum Infect Dis] 2019 Jun 01; Vol. 6 (7), pp. ofz262. Date of Electronic Publication: 2019 Jun 01 (Print Publication: 2019). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Published by Oxford University Press on behalf of the Infectious Diseases Society of America Country of Publication: United States NLM ID: 101637045 Publication Model: eCollection Cited Medium: Print ISSN: 2328-8957 (Print) Linking ISSN: 23288957 NLM ISO Abbreviation: Open Forum Infect Dis Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Cary, NC : Published by Oxford University Press on behalf of the Infectious Diseases Society of America, [2014]- |
| مستخلص: | Objective: Candida auris is a globally emerging pathogen associated with significant mortality. This pathogen frequently is misidentified by traditional biochemical methods and is resistant to commonly used antifungals. The echinocandins currently are recommended as the first-line treatment for C. auris infections. The objective of this work is to demonstrate the challenges associated with C. auris in the real-world setting. Methods: A 54-year-old male presented to our institution for concerns of sepsis on multiple occasions over a 5-month period. Eleven urine cultures were positive over this timeframe for yeast (9 unidentified Candida isolates and 2 C. lusitaniae isolates). On day 27, the patient developed echinocandin-susceptible candidemia, which was initially identified as C. haemulonii but later accurately identified as C. auris at an outside mycology reference laboratory. Approximately 10 weeks later, the patient had a recurrence of candidemia, this time caused by an echinocandin-resistant C. auris strain. Results: Genomic DNA sequencing performed at the outside mycology reference laboratory identified a single serine to proline base pair change at position 639 (S639P) in the hotspot 1 region of the FKS1 gene of the echinocandin-resistant strain. Conclusions: Our experiences highlight 4 major concerns associated with C. auris: misidentification, persistent colonization, infection recurrence despite the receipt of appropriate initial therapy, and development of resistance. |
| References: | Clin Infect Dis. 2005 May 15;40(10):1465-70. (PMID: 15844069) Antimicrob Agents Chemother. 2008 Oct;52(10):3783-5. (PMID: 18676885) Int J Infect Dis. 2009 Nov;13(6):701-6. (PMID: 19155184) Clin Infect Dis. 2009 Jun 15;48(12):1695-703. (PMID: 19441981) J Clin Microbiol. 2011 Jun;49(6):2304-6. (PMID: 21490186) Indian J Med Microbiol. 2013 Jan-Mar;31(1):90-1. (PMID: 23508441) Int J Antimicrob Agents. 2014 Jan;43(1):78-81. (PMID: 24182454) Eur J Clin Microbiol Infect Dis. 2014 Sep;33(9):1489-96. (PMID: 24715154) Clin Infect Dis. 2016 Feb 15;62(4):e1-50. (PMID: 26679628) Med Mycol Case Rep. 2016 Mar 21;11:24-6. (PMID: 27069849) J Pharm Pract. 2017 Jun;30(3):347-352. (PMID: 27112735) New Microbes New Infect. 2016 Jul 29;13:77-82. (PMID: 27617098) Antimicrob Agents Chemother. 2017 Jan 24;61(2):. (PMID: 27855078) J Clin Microbiol. 2017 Feb;55(2):638-640. (PMID: 27881617) Am J Transplant. 2017 Jan;17(1):296-299. (PMID: 28029734) Emerg Infect Dis. 2017 Feb;23(1):. (PMID: 28098529) Rev Iberoam Micol. 2017 Jan - Mar;34(1):23-27. (PMID: 28131716) PLoS Pathog. 2017 May 18;13(5):e1006290. (PMID: 28542486) J Infect. 2017 Oct;75(4):373-376. (PMID: 28579303) Infect Control Hosp Epidemiol. 2018 Jan;39(1):53-57. (PMID: 29208056) Diagn Microbiol Infect Dis. 2018 Mar;90(3):196-197. (PMID: 29307565) J Antimicrob Chemother. 2018 Apr 1;73(4):891-899. (PMID: 29325167) Microbiologyopen. 2018 Aug;7(4):e00578. (PMID: 29345117) Emerg Microbes Infect. 2018 Mar 29;7(1):43. (PMID: 29593275) PLoS One. 2018 Apr 9;13(4):e0195743. (PMID: 29630658) Mycoses. 2018 Jul;61(7):498-505. (PMID: 29655180) Nan Fang Yi Ke Da Xue Xue Bao. 2018 Apr 20;38(4):466-470. (PMID: 29735449) Emerg Infect Dis. 2018 Oct;24(10):1816-1824. (PMID: 30226155) Chemotherapy. 1973;18(6):321-36. (PMID: 4741211) |
| فهرسة مساهمة: | Keywords: Candida auris; FKS; antifungal resistance; candidemia; echinocandin |
| تواريخ الأحداث: | Date Created: 20190709 Latest Revision: 20220409 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC6602379 |
| DOI: | 10.1093/ofid/ofz262 |
| PMID: | 31281859 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2328-8957 |
|---|---|
| DOI: | 10.1093/ofid/ofz262 |